CMS Reverses Bone Growth Stimulator Reimbursement Cut, Boosting Orthofix
OFIX sits 22% above its 52-week low of $8.85.
Summary
The Centers for Medicare & Medicaid Services (CMS) has restored Medicare reimbursement rates for Orthofix's bone growth stimulators to their original levels. This reverses a previous decision in May that Orthofix stated would lead to a 10% decrease in average reimbursement rates and prevent the company from generating positive cash flow for the year. The prior cut had led Orthofix to lower its full-year 2026 financial guidance and withdraw long-term targets on May 21st. This positive development, announced via an 8-K filing today, removes a significant financial headwind and should materially improve the company's revenue and cash flow outlook.
At the time of this announcement, OFIX was trading at $10.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.8M. The 52-week trading range was $8.85 to $16.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.